UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000022325
Receipt number R000024991
Scientific Title The Epidemiological study on the incidence of childhood community acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Chiba city, Japan
Date of disclosure of the study information 2016/05/16
Last modified on 2020/05/19 12:44:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The Epidemiological study on the incidence of childhood community acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Chiba city, Japan

Acronym

The Epidemiological study on the incidence of childhood community acquired pneumonia in Chiba city, Japan

Scientific Title

The Epidemiological study on the incidence of childhood community acquired pneumonia and bacteriologically confirmed pneumococcal pneumonia in Chiba city, Japan

Scientific Title:Acronym

The Epidemiological study on the incidence of childhood community acquired pneumonia in Chiba city, Japan

Region

Japan


Condition

Condition

pneumonia

Classification by specialty

Pediatrics Child

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The aim of the study is to clarify the epidemiologic and microbiologic picture of community acquired pneumonia in children after the introduction of pneumococcal conjugate vaccine in Japan.

Basic objectives2

Others

Basic objectives -Others

The aim of the study is to clarify the epidemiologic and microbiologic picture of pneumococcal pneumonia pneumonia in children after the introduction of 13 valent pneumococcal conjugate vaccine in Japan.

Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Not applicable


Assessment

Primary outcomes

To investigate the incidence of CAP after the introduction of PCV13 in Chiba city, Japan

Key secondary outcomes

To reveal the incidence of bacteriologically confirmed PP in children after the introduction of PCV13


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

4 weeks-old <=

Age-upper limit

192 weeks-old >

Gender

Male and Female

Key inclusion criteria

pediatric inpatient with community acquired pneumonia who residents in Chiba city

Key exclusion criteria

none

Target sample size

700


Research contact person

Name of lead principal investigator

1st name Naruhiko
Middle name
Last name Ishiwada

Organization

Medical Mycology Research Center, Chiba University

Division name

Department of Infectious Diseases

Zip code

260-8673

Address

1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba

TEL

0432262799

Email

ishiwada@faculty.chiba-u.jp


Public contact

Name of contact person

1st name Naruhiko
Middle name
Last name Ishiwada

Organization

Medical Mycology Research Center, Chiba University

Division name

Department of Infectious Diseases

Zip code

260-8673

Address

1-8-1 Inohana Chuo ku Chibashi

TEL

0432262799

Homepage URL


Email

ishiwada@faculty.chiba-u.jp


Sponsor or person

Institute

Department of Infectious Diseases, Medical Mycology Research Center, Chiba University

Institute

Department

Personal name



Funding Source

Organization

Pfizer Japan Inc.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Mycology Research Center

Address

1-8-1, Inohana, Chuo-ku, Chiba-shi

Tel

0432262799

Email

ishiwada@faculty.chiba-u.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

千葉大学医学部附属病院 千葉県こども病院 千葉市立海浜病院 千葉メディカルセンター


Other administrative information

Date of disclosure of the study information

2016 Year 05 Month 16 Day


Related information

URL releasing protocol

https://www.ncbi.nlm.nih.gov/pubmed/32299523

Publication of results

Partially published


Result

URL related to results and publications

https://www.ncbi.nlm.nih.gov/pubmed/32299523

Number of participants that the trial has enrolled

1399

Results

The CAP hospitalisation rate per 1000 child-years was 17.7, 14.3 and 9.7 in children aged <5 years and 1.18, 2.64 and 0.69 in children aged 5-15 years in 2008, 2012 and 2018, respectively. There was a 45% and 41% reduction in CAP hospitalisation rates, between the pre-PCV7 and PCV13 periods, respectively. Significant reductions occurred in the proportion of CAP due to PP and PCV13 serotypes. Conversely, no change occurred in the proportion of CAP caused by H. influenzae.

Results date posted

2020 Year 05 Month 19 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

This observational hospital-based surveillance study included children aged equal and less than 15 years, admitted to hospitals in and around Chiba City, Japan.

Participant flow

Participants had bacterial pneumonia based on a positive blood or sputum culture for bacterial pathogens. Serotype and antibiotic-susceptibility testing of Streptococcus pneumoniae and Haemophilus influenzae isolates from patients with bacterial pneumonia were assessed.

Adverse events

None

Outcome measures

The incidence of hospitalized CAP in children
The rate of bacterial pneumonia
serotype and antimicrobial susceptibility of S. pneumoniae and H. influenzaeisolated from pediatric CAP

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Main results already published

Date of protocol fixation

2016 Year 03 Month 31 Day

Date of IRB

2016 Year 02 Month 01 Day

Anticipated trial start date

2016 Year 04 Month 01 Day

Last follow-up date

2019 Year 03 Month 31 Day

Date of closure to data entry

2022 Year 04 Month 30 Day

Date trial data considered complete

2022 Year 09 Month 30 Day

Date analysis concluded

2022 Year 10 Month 31 Day


Other

Other related information

observational population-based cohort study

Target population
All children living in Chiba city who were
admitted to hospitals during the study period(April, 2016-March, 2019)


Management information

Registered date

2016 Year 05 Month 16 Day

Last modified on

2020 Year 05 Month 19 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000024991


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name